AstraZeneca’s Covid-19 vaccine shows 79% efficacy in US clinical trial
AZD1222 showed 79% vaccine efficacy in preventing symptomatic Covid-19 and 100% efficacy against severe Covid-19 and hospitalisation
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Mar 21
AZD1222 showed 79% vaccine efficacy in preventing symptomatic Covid-19 and 100% efficacy against severe Covid-19 and hospitalisation
12 Mar 21
The MoH analysis showed at least 97% vaccine effectiveness against symptomatic Covid-19 cases, and 94% against asymptomatic SARS-CoV-2…
26 Feb 21
The Phase 1/2/3 trial evaluates the safety and tolerability of a third dose of BNT162b2 and its effectiveness…
23 Feb 21
The Phase 2 trial is designed to determine the appropriate antigen dosage for Phase 3 evaluation of their…
19 Feb 21
The Phase 2/3 study will enrol healthy pregnant women, aged 18 years and older, and vaccinate them during…
04 Feb 21
The vaccine demonstrated 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase 3…
01 Feb 21
The vaccine showed 72% effectiveness in the US and an overall 66% effectiveness in preventing Covid-19 after 28…
28 Dec 20
Covaxx, is currently conducting phase 1 clinical trial for the vaccine candidate
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Dec 20
Treatment using tezepelumab did not meet the primary endpoint of statistically significant reduction in the daily OCS dose,…
09 Dec 20
In the interim analysis, the vaccine showed efficacy in preventing Covid-19, with no severe cases or hospitalisations after…